October 14, 2021 – A promising approach for preventing cognitive and behavioral impairment following ischemic events such as cardiac arrest and stroke. Aurora, CO – Neurexis Therapeutics, Incorporated, announces it has been awarded >> Read More

January 4, 2021 – CBSA President & CEO, Jennifer Jones Paton, asked Michael Artinger, PhD, Neurexis’ Chief Executive Officer, CBSA’s Key Questions for Life Sciences Innovators. Neurexis Therapeutics relies on innovation to address a substantial unmet medical need: damage to the brain resulting from loss of blood flow >> Read More

June 18, 2020 – AURORA, CO – Neurexis Therapeutics, Inc. announced today that it has been approved for funding as part of the Colorado Office of Economic Development and International Trade’s (OEDIT) Advanced Industries Accelerator Program. The $250,000 Early Stage Capital and Retention Grant will be used to accelerate development of the company’s innovative therapeutic peptide >> Read More

April 8, 2020 – AURORA, CO – VIC Technology Venture Development, LLC (VIC) announced today the formation of Neurexis Therapeutics, Inc. to develop a new medication for the prevention of brain damage following ischemic events such as stroke. Licensed from the University of Colorado Anschutz Medical Campus >> Read More